IPP Bureau
Novo Nordisk invests €432 million to expand Athlone facility for global Wegovy pill supply
By IPP Bureau - March 02, 2026
The construction projects, which have already begun, will be finalised gradually from the end of 2027 through 202
Blue Jet Healthcare breaks ground on Rs. 2,300 crore pharma plant in Andhra Pradesh
By IPP Bureau - March 02, 2026
The facility is expected to become operational by FY2028-29
Emcure partners with Roche to boost nephrology and transplant care in India
By IPP Bureau - March 02, 2026
Emcure to distribute Roche's kidney transplant and anemia drugs in India
Roche’s Fenebrutinib moves closer to being first BTK inhibitor for relapsing and progressive MS
By IPP Bureau - March 02, 2026
Fenebrutinib has the potential to become the first and only high-efficacy oral, brain-penetrant treatment for both RMS and PPMS, showing a profound benefit on relapsing and progressive disease biology
Lupin receives EIR from FDA for its Goa facility
By IPP Bureau - February 28, 2026
The EIR was issued following an inspection of the facility from November 10 to November 21, 2025
Zydus hits Keytruda biosimilar milestone with successful FYB206 trial, targets USFDA filing
By IPP Bureau - February 28, 2026
Zydus has in-licensed FYB206, a proposed biosimilar to immuno-oncology therapy Keytruda (pembrolizumab), exclusively from Formycon AG for the U.S. and Canadian markets
Glenmark Pharmaceuticals USA to launch sodium phosphates injection
By IPP Bureau - February 28, 2026
The product addresses a market with approximately $66.8 million in annual sales as of December 2025.
Lupin’s Vinita Gupta honoured as CNBC Changemaker for revolutionising U.S. healthcare access
By IPP Bureau - February 28, 2026
Vinita has made expansion in the U.S. a core pillar of Lupin’s worldwide growth strategy
Lupin tops world pharma and all Indian sectors in S&P ESG rankings
By IPP Bureau - February 28, 2026
Lupin attained a score of 91 out of 100, establishing itself as the leading pharmaceutical company globally
Merck’s KEYTRUDA shows significant survival boost in platinum-resistant ovarian cancer
By IPP Bureau - February 28, 2026
KEYTRUDA had previously met its primary endpoint of progression-free survival in all patients
Eli Lilly and Incyte score key win for teens with severe alopecia areata in Europe
By IPP Bureau - February 28, 2026
AA, a chronic immune disease, can cause extensive and unpredictable hair loss
Thermo Fisher launches genetic test to personalize transplant drug dosing
By IPP Bureau - February 28, 2026
The TacroType test provides actionable genetic insights to help clinicians understand how individual patients metabolize tacrolimus
Eli Lilly’s orforglipron outshines oral semaglutide in landmark diabetes trial
By IPP Bureau - February 28, 2026
The results, published in The Lancet, showed orforglipron delivered significantly greater reductions in both A1C and body weight across primary and key secondary endpoints
Novartis completes $12 billion acquisition of Avidity Biosciences
By IPP Bureau - February 28, 2026
The deal was executed via a merger of Novartis’ wholly owned subsidiary, Ajax Acquisition Sub, Inc., into Avidity
